AstraZeneca has announced plans to build a new drug substance manufacturing facility in the Commonwealth of Virginia. The company, which develops and produces innovative medicines for a range of diseases, has invested a multi-billion dollar sum into the project, which is expected to create hundreds of highly skilled new jobs.
The planned facility will be AstraZeneca’s largest single manufacturing investment globally and will support production of drug substances for its weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule products. The site will manufacture small molecules, peptides, and oligonucleotides, and will integrate technologies such as AI, automation, and data analytics to optimize production.
This investment is part of AstraZeneca’s $50 billion commitment to expand its U.S. R&D and manufacturing footprint by 2030. Additional investments include expansions and new facilities across Maryland, Massachusetts, Indiana, Texas, and California.
What people are saying
In a recent quote, Pascal Soriot, Chief Executive Officer, AstraZeneca, said, “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines."
Governor Glenn Youngkin, Commonwealth of Virginia, added, “I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”
Manufacturers investing in Virginia
Verne invests $4.5M to open hydrogen storage vessel manufacturing facility in Pennsylvania
The new facility will create at least 61 full-time jobs and strengthen Pennsylvania’s clean energy and advanced manufacturing sectors.
Micron Technology invests $30B to expand memory manufacturing facilities in Idaho and Virginia
The expanded production will help meet increasing demand driven by AI and support Micron’s goal of producing 40% of its DRAM in the U.S.
Nightingale Ice Cream Sandwiches invests $5.8M to open ice cream manufacturing facility in Virginia
The company’s new location will also serve as its corporate headquarters as it expands operations in Richmond.
Investing in American manufacturing in 2025
This map shows where manufacturers are choosing to invest their resources, whether they are building new production facilities or expanding existing plants.
